Skip to main content
. 2015 Dec 16;33(51):7357–7363. doi: 10.1016/j.vaccine.2015.10.022

Table 5.

Total financial and economic costs of three vaccine introductions in Rwanda in 2012 US$.

Prevnar RotaTeq Gardasil
Target number of children to be vaccinated 376,202 394,473 91,317
Financial costs
 Startup
  Micro-planning $4612 $4607 $13,197
  Training $23,959 $12,231 $44,283
  Social Mobilization/Information, Education, and Communication (IEC) $30,170 $30,170 $53,125
   Sub-total $58,741 $47,008 $110,605
 Recurrent
  Service delivery $735,009
  Vaccines/injection supplies procurement $565,366 $673,207 $156,503
  Monitoring & evaluation (M&E), Supervision $55,767 $61,902 $59,873
  Waste management $46,253 $4694 $36,139
   Sub-total $667,386 $739,803 $987,524
 Capital: cold chain



Total $726,127 $786,812 $1,098,129



Economic costs
 Startup
  Micro-planning $59,543 $56,151 $84,146
  Training $111,412 $52,293 $107,628
  Social Mobilization/IEC $34,885 $34,885 $79,745
   Sub-total $205,840 $178,214 $271,519
 Recurrent
  Service delivery $243,662 $239,557 $904,918
  Vaccines/injection supplies procurement $4,471,911 $6,548,471 $1,951,594
  M&E, Supervision $83,541 $83,324 $82,057
  Waste management $59,161 $5,164 $48,672
   Sub-total $4,858,275 $6,876,516 $2,987,241
 Capital: cold chain $23,645 $32,895 $22,969



Total $5,087,760 $7,052,538 $3,281,720